fenofibrate has been researched along with folic acid in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Dierkes, J; Luley, C; Westphal, S | 2 |
| Banditt, P; Dierkes, J; Kunstmann, S; Lössner, A; Luley, C; Westphal, S | 1 |
| Ceska, R; Grauová, B; Kozich, V; Melenovský, V; Stulc, T | 1 |
| Császár, A; Márk, L | 1 |
| Holubec, L; Mayer, O; Pikner, R; Simon, J; Subrt, I | 1 |
| Ceska, R; Grauova, B; Haas, T; Hradec, J; Kozich, V; Krijt, J; Malik, J; Melenovsky, V; Stulc, T; Wichterle, D | 1 |
| Holubec, L; Mayer, O; Pikner, R; Simon, J; Trefil, L | 1 |
3 review(s) available for fenofibrate and folic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6 | 2002 |
Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management.
Topics: Arteriosclerosis; Fenofibrate; Folic Acid; Humans; Hyperhomocysteinemia; Hypolipidemic Agents; Kidney; Vitamin B 12 | 2003 |
6 trial(s) available for fenofibrate and folic acid
| Article | Year |
|---|---|
Serum homocysteine increases after therapy with fenofibrate or bezafibrate.
Topics: Adult; Bezafibrate; Chromatography, High Pressure Liquid; Fenofibrate; Folic Acid; Hematinics; Homocysteine; Humans; Hyperhomocysteinemia; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pilot Projects; Pyridoxine; Vitamin B 12 | 1999 |
Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate.
Topics: Cross-Over Studies; Double-Blind Method; Fenofibrate; Folic Acid; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyridoxine; Vitamin B 12; Vitamins | 2001 |
Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.
Topics: Arteriosclerosis; Dietary Supplements; Drug Synergism; Drug Therapy, Combination; Fenofibrate; Folic Acid; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Pilot Projects; Risk Factors | 2001 |
Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration.
Topics: Aged; Anticholesteremic Agents; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Folic Acid; Hematinics; Homocysteine; Humans; Hyperhomocysteinemia; Hypolipidemic Agents; Indoles; Male; Middle Aged; Prospective Studies | 2003 |
Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
Topics: Cholesterol; Creatinine; Cysteine; Female; Fenofibrate; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Statistics as Topic; Triglycerides; Uric Acid | 2003 |
Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Drug Therapy, Combination; Endothelium, Vascular; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Folic Acid; Homocysteine; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Prospective Studies; Thrombomodulin; Treatment Outcome; Triglycerides; Vitamin B Complex; von Willebrand Factor | 2006 |
7 other study(ies) available for fenofibrate and folic acid
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |